Systemic Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Systemic Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 3]
Phase 3 trial update for baricitinib in children aged 1 year to under 18 with systemic juvenile idiopathic arthritis (sJIA); study status is…
-
CLINICAL_TRIALS trial_result · 2026-07-16Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 3]
Phase 3 trial investigating baricitinib (LY3009104) in children aged 1 year to under 18 with systemic juvenile idiopathic arthritis; status …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
This clinical trial aims to study the natural history, genetics, and pathophysiology of systemic juvenile idiopathic arthritis and adult-ons…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) [Phase 2]
This clinical trial update describes a Phase 2 repeated-dose study of sarilumab in children and adolescents with systemic juvenile idiopathi…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
A clinical trial is evaluating canakinumab for Familial Mediterranean Fever and Still's disease (including systemic juvenile idiopathic arth…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
This clinical trial update describes an ongoing study on the natural history, pathogenesis, and outcomes of autoinflammatory diseases includ…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases
This clinical trial update investigates whether IL-18 and IL-18 binding protein can serve as diagnostic biomarkers to differentiate systemic…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE [Phase 3]
A Phase 3 clinical trial evaluated the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics of emapalumab in children and a…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
A RaDiCo Acostill cohort study led by INSERM in France is currently recruiting to study Still's disease, including adult-onset Still's disea…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. [Phase 3]
Phase 3 trial in pediatric and adolescent patients with active systemic juvenile idiopathic arthritis comparing oral upadacitinib with subcu…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) [Phase 3]
A Phase 3 clinical trial evaluating baricitinib (LY3009104) in participants aged 1 year to under 18 with systemic juvenile idiopathic arthri…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Ilaris NIS in Korea
Novartis' canakinumab (Ilaris) is the subject of a Korea-based non-interventional study that is currently recruiting. The study covers hered…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT [Phase 2]
Phase 2 study evaluating reduced-intensity conditioning for non-malignant disorders undergoing umbilical cord blood transplantation (UCBT), …
-
FDA approval · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.
-
FDA label_change · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) submitted by Genentech, Inc., related to changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Assessment of Macrophage Activation syndromE in STill's Disease in Italy
A clinical trial evaluating macrophage activation syndrome in Still's disease (systemic juvenile idiopathic arthritis and adult-onset Still'…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA [Phase 3]
Phase 3 safety, efficacy, and pharmacokinetics study of tofacitinib in pediatric patients with systemic juvenile idiopathic arthritis has co…
-
FDA approval · 2025-05-12FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-03-13FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS research · 2025-03-05Clinical Trial Update: A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) [Phase 3]
Phase 3 clinical trial evaluating Anakinra in Japanese patients with systemic juvenile idiopathic arthritis and adult-onset Still's disease …
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Assessment of Macrophage Activation syndromE in STill's Disease
A completed clinical trial assessing macrophage activation syndrome in Still's disease, including adult-onset Still's disease and juvenile-o…
-
CLINICAL_TRIALS research · 2024-09-23Clinical Trial Update: To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. [NA]
A clinical trial is evaluating the efficacy and safety of Genalumab for injection in patients with active systemic juvenile idiopathic arthr…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
This clinical trial update reports long-term safety data for anakinra (Kineret) in patients with systemic juvenile idiopathic arthritis (SJI…
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
Clinical trial update shows a research database for Still's disease in children and adults is currently recruiting, sponsored by Hospices Ci…